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Supplementary Figure S1
 
Figure S1. K562 cells and SH-SY5Y cells express CD47 isoform 2 and isoforms 3 and 4, but CD47 isoforms 3 and 4 were only detected at the surface 
of SH-SY5Y cells. (A) Cells were lysed and separated by SDS-PAGE (106 cells/lane). Western blots were then probed with anti-CD47out1 (Total), anti-
CD47 isoform 2 or anti-CD47 isoforms 3 and 4 (protein band indicated by *) (n=2). Total cell, and cell surface immunoprecipitations followed by internal 
immunoprecipitations, were carried out on 5 - 10 x 106 K562 cells (B) and SH-SY5Y cells (C). The eluates were separated by SDS-PAGE against K562 and 
SH-SY5Y cell lysates (106 cells/lane). Western blots were then probed with anti-CD47 isoform 2 or anti-CD47 isoforms 3 and 4 (n=2). 
Supplementary Figure S2.  
 
Figure S2 The hallmarks of protein 4.2 deficiency are recapitulated following shRNA-mediated knockdown of protein 4.2 via lentiviral transduction. 
Erythroblasts were transduced with lentiviral pLKO.1 protein 4.2 shRNA1, or a scramble shRNA control, as detailed in the methods. (A and C) 1.5 x 106 
protein 4.2 deficient and scramble control erythroblasts were incubated with Hoechst for 45 minutes at 37°C, to separate erythroblasts from reticulocytes and 
nuclei, and fixed in 1% PFA and 0.0075% glutaraldehyde24 prior to labelling with BRIC32 (CD47) or BRIC222 (CD44) for 30 minutes at 4°C. The cells were 
then incubated with an APC-conjugated monoclonal rat anti-mouse IgG1 secondary, and membrane protein expression was assessed by flow cytometry. (A) 
Every 24 hours during differentiation expression of CD47 and CD44 on erythroblasts was assessed by flow cytometry (n=3 for each time point). (B) Filtered 
reticulocytes generated from in vitro cultured protein 4.2 deficient erythroblasts compared to Scramble shRNA control erythroblast, were lysed and separated 
by SDS-PAGE (1.8 x 105 reticulocytes/lane). Western blots were probed with rabbit anti-C terminal band 3 antibody (YNTU), BRIC273 (anti-protein 4.2), 
BRIC222 (anti-CD44), anti-CD47 (CD47out1) and anti-GAPDH as a loading control (n=2). (C) Average protein expression of CD47 and CD44 on 
reticulocytes between 96-144 hours post-differentiation (Average MFI as a % of the scramble control ± SEM (n=3 at each time point), *** p ≤ 0.001; ** p ≤ 
0.01 using the Students T test). Emissions from 10,000 events were detected using a MACSQuant Analyser 10 flow cytometer and data was analysed using 
FlowJo version 10. 
 
 
 
 
 
 
 
 
Supplementary Figure S3 
 
Figure S3. Inhibition of CD47 endocytosis in K562 cells. 1 x 106 K562 cells were incubated with MiTMAB (30µM), Dynasore (80µM), Pitstop 2 (30µM), 
Sucrose (15mM) or a DMSO control for 20 minutes at 37°C. K562 cells were then stained with (A) BRIC32 (anti-CD47), or (B) P5D2 (anti-β1 Integrin) 
followed by APC-conjugated monoclonal IgG1 anti-mouse secondary antibody, before being assessed by flow cytometry (Average MFI as a % of the DMSO 
controls ± SD (n=4); *** p ≤ 0.001; ** p ≤ 0.01, * p ≤ 0.05 using the Students T test). 10,000 events were detected using a MACSQuant Analyser 10 flow 
cytometer and data was analysed using FlowJo version 10. 
Supplemental Table 1. Summary of the proteomic profile of peptides detected following BRIC126 immunoprecipitations (IP) in K562 cells, EXP, T0 
and T48 erythroblasts, and mature erythrocytes (RBCs). The total BRIC126 IP peptides and IgG peptides are shown alongside the ratio total/IgG. Clean 
total (Tot) peptides are underlined and bold. * Indicates no ratio due to absence of IgG control peptides . Peptides detected in the BRIC126 IP that are less 
than 2-fold enriched, compared to the isotype control (IgG) are highlighted in grey. 
Accession 
Number 
Protein Description K562 cells EXP T0 T48 Mature RBCs 
Tot IgG Ratio Tot IgG Ratio Tot IgG Ratio Tot IgG Ratio Tot IgG Ratio 
P60709 Actin, cytoplasmic 1 71  33 2.2 242  109 2.2 194  114 1.7 18 42 0.4 155  139 1.1 
P61158 Actin-related protein 3 5 - * 8  6 1.3 13  6 2.2 - - - 2 2 
1 
O43707 Alpha-actinin-4 8 - * 59  20 3.0 86  45 2.0 - - - 25  29 0.9 
Q562R1 β-actin like protein 2 14  3 4.7 45  19 2.4 42  25 1.7 - - - 35  39 0.9 
Q96C19 EF hand containing protein D2 7 - * 12  3 4 15  6 2.5 - - - 6 - * 
P15311 Ezrin 12  6 2 - - - - - - - - - 6  14 0.4 
P47756 F-actin capping protein subunit β 7  1 7 17  6 2.8 12  9 1.3 - - - 3  3 1 
P21333 Filamin A 42  15 2.8 54  6 9 17  25 0.7 - - - 20  62 0.3 
Q08722 Leucocyte surface antigen, CD47 6  1 6 7  2 3.5 8  4 2 6 5 1.2 14  6 2.3 
Q9UHB6 LIMA1 - - - 7  2 3.5 27  5 5.4 - - - 3  5 0.6 
P26038 Moesin 22  7 3.1 3  1 3 3  5 0.6 2 7 0.3 4  23 0.2 
O94832 Myosin-Id 12  2 6 20  12 1.7 34  19 1.8 - - - 20  37 0.5 
P35579 Myosin-9 228  72 3.2 374  166 2.3 224  185 1.2 5 17 0.3 302  410 0.7 
P35580 Myosin-10 154  37 4.2 240  132 1.8 204  172 1.2 2 7 0.3 196  284 0.7 
P12829 Myosin light chain 4 13  2 6.5 8  1 8 26  5 5.2 1 1 1 19  25 0.8 
P35241 Radixin 10  5 2 - - - - - - - - - - - - 
P02549 Spectrin α chain, erythrocyte - - - 19 - * 30 27 1.1 1 5 0.2 - - - 
P11277 Spectrin β chain, erythrocyte - - -  9  1  9 27  23 1.2 - - - - - - 
Q9NYL9 Tropomodulin-3 - - - 8 - * 8  2 4 - - - 2  1 2 
P06753 Tropomyosin α-3 chain 9  1 9 3  3 1 5 - * - - - 8 5 1.6 
Q71U36 Tubulin α-1A chain 25  17 1.5 14 - * 23 - * 11 28 0.4 - - - 
P62988 Ubiquitin 19  3 6.3 2  2 1 4  3 1.3 7 9 0.8 4  20 0.2 
P68036 Ubiquitin-conjugated enzyme E2 L3 14 5 2.8 - - - - - - - - - 4 - * 
P08670 Vimentin - - - 5 - * 2 - * - - - 10  13 0.8 	
 
 
  
 
